
|Articles|October 18, 2012
Low-dose SSRI formulation shows promise for vasomotor symptoms
A new formulation of a selective serotonin receptor inhibitor (SSRI)-low-dose mesylate of paroxetine (LDMP)-shows promise for reducing vasomotor symptoms of menopause, according to results of two studies presented at the North American Menopause Society (NAMS) conference.
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Sex toy use linked to orgasm frequency in women over 60
2
Contemporary OB/GYN week in review: Sleep education, AI in IVF, and more
3
Major gaps found in endometriosis policies worldwide
4
Holiday foodborne illnesses and pregnancy: What ob-gyns should remind patients
5











